Stock Taper 
Nanobiotix S.A., a Paris-based biotech founded in 2003, develops cancer treatments like NBTXR3, a nanoparticle therapy for various cancers, with a partnership with LianBio for commercialization in Asia.
NBTXR3 is a hafnium oxide nanoparticle-based radioenhancer injected into tumors to amplify radiotherapy's cancer-killing effects while sparing healthy tissue, currently in multiple clinical trials.
In a pivotal move to solidify its financial future, Nanobiotix entered into a royalty-based financing agreement for up to $71 million with HealthCare Royalty. This non-dilutive funding was a notable event as it addressed concerns about the company's cash runway, extending its operational capacity into early 2028 and providing the capital to advance its nanotherapeutic platforms without diluting shareholder equity.
In a pivotal financial move, Nanobiotix entered into a non-dilutive royalty financing agreement with HealthCare Royalty (HCRx) for up to $71 million. This strategic transaction provides the company with significant long-term capital to fund its operations and advance the global development of its lead product candidate, NBTXR3, without diluting shareholder equity.
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report)'s stock price gapped down before the market opened on Thursday. The stock had previously closed at $31.16, but opened at $29.99. Nanobiotix shares last traded at $29.8790, with a volume of 9,803 shares traded. Wall Street Analysts Forecast Growth Several equities analysts have issued reports
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) saw an uptick in trading volume on Wednesday. 90,160 shares changed hands during trading, an increase of 1% from the previous session's volume of 88,938 shares. The stock last traded at $32.0210 and had previously closed at $31.50. Analysts Set New Price Targets NBTX has
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company's executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in publicly listed biotechnology companies in Europe and the United States. He succeeds Bart Van Rhijn, who will step down as chief financial & business officer and member of the executive board after five years of service to the Company.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 IBRX | $9.99 | COMPARE |
 SNDX | $17.04 | COMPARE |
 GHRS | $21.46 | COMPARE |
 TYRA | $20.01 | COMPARE |
 SVRA | $4.66 | COMPARE |
 KURA | $10.40 | COMPARE |
 ABUS | $4.46 | COMPARE |
 AVBP | $16.48 | COMPARE |
